Journal of Neuro-Ophthalmology:
Relationship Between NMO-Antibody and Anti–MOG Antibody in Optic Neuritis
Kezuka, Takeshi MD, PhD; Usui, Yoshihiko MD, PhD; Yamakawa, Naoyuki PhD; Matsunaga, Yoshimichi MD; Matsuda, Ryusaku MD; Masuda, Masayuki MD; Utsumi, Hiroya MD, PhD; Tanaka, Keiko MD, PhD; Goto, Hiroshi MD, PhD
Department of Ophthalmology (TK, YU, NY, YM, RM, HG) and Division of Neurology (MM, HU), Tokyo Medical University, Tokyo, Japan; and Department of Neurology (KT), Kanazawa Medical University, Ishikawa, Japan.
Address correspondence to Takeshi Kezuka, MD, PhD, Department of Ophthalmology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan; E-mail: firstname.lastname@example.org
Supported in part by a follow-up grant for the Tokyo Medical University research project and in part by a Grant-in-Aid for Scientific Research from the Japanese Ministry of Education and by the Human Health Science Foundation.
The authors report no conflicts of interest.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (http://www.jneuro-ophthalmology.com).
Background: Damage to astrocytes by anti-aquaporin-4 antibody (AQP4-Ab), also known as NMO antibody, has been implicated as the cause of neuromyelitis optica. Myelin oligodendrocyte glycoprotein (MOG) is well known as the causative protein of multiple sclerosis (MS). MOG antigen is currently considered as a cause of optic neuritis (ON) associated with MS because immunization with MOG antigen derived from oligodendrocytes induces murine ON with myelitis. We investigated the relationship between NMO antibody (NMO-Ab) and anti-MOG antibody (MOG-Ab) and potential in patients with ON for recovery of vision.
Methods: Thirty-three eyes of 23 patients with ON were studied. At presentation, serum NMO-Ab was measured by immunofluorescence using HEK 293 cells transfected with AQP4–GFP, and anti-MOG1–125 antibody was measured by enzyme-linked immunosorbent assay. MOG-Ab seropositivity was defined by comparing with MOG-Ab level obtained from 8 healthy normal subjects.
Results: Eleven (47%) of 23 ON patients were NMO-Ab seropositive, while 8 (34%) of the 23 patients were MOG-Ab seropositive. Six (26%) of 23 patients were seropositive for both NMO-Ab and MOG-Ab. Ten (43%) of 23 patients were seronegative for both antibodies. Three (50%) of 6 eyes of patients seropositive for both antibodies did not respond to corticosteroid pulse therapy and plasmapheresis, and visual acuity remained unchanged. In the NMO-Ab(−)/MOG-Ab(−) group, visual acuity improved significantly (P < 0.0001). In the other 3 groups (NMO-Ab(+)/MOG-Ab(+), NMO-Ab(+)/MOG-Ab(−), and NMO-Ab(−)/MOG-Ab(+)), visual acuity did not change significantly (P = 0.53, 0.42, and 0.45, respectively).
Conclusion: NMO-Ab and MOG-Ab could be potential biomarkers to determine visual prognosis in patients with ON.
Optic neuritis (ON) is characterized by acute or subacute painful loss of central vision that may progress over a period of 7–10 days (1). ON may be associated with acute inflammatory demyelinating diseases, such as multiple sclerosis (MS) or neuromyelitis optica (NMO) (1–3).
NMO-IgG, a serum immunoglobulin autoantibody (NMO-Ab) directed against aquaporin-4 (AQP4), is a pathological effector in NMO. It binds to astrocytic transmembrane protein AQP4, the predominant water channel in the central nervous system (CNS) (4–6). Expression of NMO-Ab in the brain, spinal cord, and optic nerve is associated with astrocyte membranes that closely appose endothelial cell basal membranes (7). NMO-Ab titers correlate with disease activity in NMO relapse in some patients followed longitudinally (8). In patients with recurrent ON, NMO-Ab seropositivity predicts poor visual outcome and development of other neurologic involvement, particularly transverse myelopathy (9).
Myelin oligodendrocyte glycoprotein (MOG) is a minor myelin antigen and constitutes only 0.05% of CNS myelin proteins compared to 30% for myelin basic protein (MBP) and 50% for proteolipid protein (PLP) (10). Administration of anti-MOG antibodies (MOG-Ab) into CNS tissue leads to extensive demyelination in animal models (11). Humoral immunity against MOG correlates with demyelinating activity in chronic relapsing experimental autoimmune encephalomyelitis (EAE) (12). The relevance of MOG as a T-cell autoantigen was investigated by comparing the response to MOG of peripheral blood cells from MS patients and control individuals, and the results implicated the possibility of MOG as a primary target myelin antigen in the pathogenesis of MS (13). The pathophysiological significance of MOG-specific autoantibodies in MS remains controversial, but study in a primate model of MOG-induced EAE showed that demyelination is mediated by MOG-specific antibodies directed against conformational rather than linear MOG epitopes, suggesting functional segregation of pathogenic vs nonpathogenic anti-MOG antibodies in human disease (14).
We investigated the relationship between NMO-Ab and MOG-Ab in ON patients to determine if there was any relationship between the presence of these antibodies and visual outcome.
Patients and Blood Samples
Patients with a diagnosis of ON were recruited who fulfilled the following criteria: 1) tested for NMO-Ab and MOG-Ab between 2007 and 2010 at the Tokyo Medical University; 2) had at least 2 documented episodes of ON separated by 1 month before NMO-Ab and MOG-Ab measurements were obtained; and 3) were not being treated with corticosteroid or other medications known to affect the immune system. Diagnosis of ON was based on acute or subacute onset vision loss, sluggish pupillary response, visual field abnormality, and contrast enhancement of the affected optic nerve on MRI. Venous heparinized blood samples were obtained from patients and healthy volunteer control subjects. The ON group comprised 33 eyes of 23 consecutive outpatients (3 males and 20 females; mean age, 45.7 ± 12.8 years), and the control group consisted of 8 healthy adults. The study was approved by the Tokyo Medical University Institutional Review Board under numbers 1026 and 1262.
Treatment of ON
The patients were treated with 2 courses of corticosteroid pulse therapy. This consisted of 1,000 mg per day of methylprednisolone administered intravenously for 3 days given at a 1-week interval, followed by oral prednisone. Plasma exchange was performed by double-filtration plasmapheresis and only in patients who did not respond to pulse steroid therapy.
NMO-Ab was measured using the AQP4 antigen-presenting cells established by Tanaka et al (15). Total RNA was extracted from an adult human cerebellum from a donor bank, and DNA-encoding human aquaporin-4 (AQP4 M23 isoform; GenBank accession number U63623) was cloned by reverse transcription–polymerase chain reaction technique. Full-length complementary DNA was inserted into the XbaI site of a pEFBOS expression vector and used to transfect HEK 293 cells. The transfected HEK 293 cells were then fixed in 4% paraformaldehyde in 0.1 mM phosphate buffered saline (PBS), pH 7.4. Nonspecific binding was blocked with 10% goat serum in PBS. The cells were incubated with the patient serum for 60 minutes at room temperature and then incubated with fluorescein isothiocyanate–conjugated rabbit anti-human IgG (BD Biosciences, San Jose, CA). A SlowFade Gold antifade reagent (Molecular Probes, Carlsbad, CA) was then applied to the slide, and reactivity was verified under a fluorescence microscope.
Anti-human MOG1–125 IgG was measured by the SensoLyte Quantitative ELISA Kit (AnaSpec, Fremont, CA) (16–18). Anti-human MOG1–125 antibody concentration of the serum sample was calculated by 4-parameter logistic curve fit based on the average absorbance values. A serum MOG-Ab concentration higher than 4 standard deviations of the mean concentration in healthy controls is considered seropositive for MOG-Ab (19).
Data are presented as median values (25th to 75th percentiles). Median MOG-Ab concentration in healthy controls was 28.4 ng/mL (22.0–52.6 ng/mL). Since the 99th percentile reference value was used as the cutoff point for abnormal level, patients' samples higher than 73.5 ng/mL of anti-MOG-Ab were considered seropositive. Statistical analysis of enzyme-linked immunosorbent assay data was performed using the Mann–Whitney U test. The differences between seropositive and seronegative groups were analyzed using the Mann–Whitney U test for frequency data.
Our patient cohort consisted of 23 patients (see Table E-1, Supplemental Digital Content 1, http://links.lww.com/WNO/A26) :11 were seropositive and 12 were seronegative for NMO-Ab. Eight patients had seropositive levels of MOG-Ab while 15 did not. Our patient cohort was divided into 4 groups based on seropositivity: NMO-Ab(+)/MOG-Ab(+), NMO-Ab(+)/MOG-Ab(−), NMO-Ab(−)/MOG-Ab(+), and NMO-Ab(−)/MOG-Ab(−) (Table 1).
Median serum MOG-Ab concentration was 88.7 ng/mL (25th to 75th percentiles: 30.1–165.8 ng/mL) in NMO-Ab(+) patients and 36.3 ng/mL (23.6–57.3 ng/mL) in NMO-Ab(−) patients, with no significant difference between the 2 groups (Fig. 1). A significant difference was observed between NMO-Ab(+) patients and controls (P = 0.033) but not between NMO-Ab(−) patients and controls.
We examined the relationship between pretreatment and posttreatment visual acuity in the 4 groups of our ON patients. When comparing improvement in posttreatment visual acuity, a significant difference was observed in NMO-Ab(+)/MOG-Ab(+) patients vs NMO-Ab(−)/MOG-Ab(+) patients (P = 0.03) or vs NMO-Ab(−)/MOG-Ab(−) patients (P = 0.0003) but not vs NMO-Ab(+)/MOG-Ab(−) patients (P = 0.67). A significant difference was also found in NMO-Ab(+)/MOG-Ab(−) vs NMO-Ab(−)/MOG-Ab(+) patients (P = 0.03) or vs NMO-Ab(−)/MOG-Ab(−) patients (P = 0.0089). No significant difference was found in NMO-Ab(−)/MOG-Ab(+) vs NMO-Ab(−)/MOG-Ab(−) patients (P = 0.23).
Next, we investigated whether visual acuity outcome was improved by changing treatment for ON. The patients were treated with 2 courses of corticosteroid pulse therapy. When they did not respond to corticosteroid pulse therapy, plasmapheresis was conducted. We defined favorable visual outcome as improvement by 2 or more Snellen lines. Meaningful statistical analysis was not possible because of small number of patients, but there appeared to be a trend of better response to treatment in NMO-Ab(−)/MOG-Ab(−) patients compared to the NMO-Ab(+)/MOG-Ab(+) group.
NMO-Ab targets astrocytes of the spinal cord and optic nerves (20) and spares the cerebral hemispheres. While patients with NMO develop ON and longitudinal extensive transverse myelitis, the 2 conditions generally manifest at different points in time (21). The optic nerves are particularly more sensitive to volume changes induced by AQP4 dysfunction across the brain–blood barrier than other regions of the CNS (22). ON patients seropositive for NMO-Ab have a poor visual prognosis (23), and 12.5% of recurrent ON cases evolved to NMO (24).
The role of MOG as a T-cell autoantigen in the pathophysiology of demyelinating disease is uncertain. Peripheral blood lymphocytes of patients with MS show a greater proliferative response to MOG compared to other antigens, including MBP and PLP (13). Yet Lim et al (24) found that the presence of MOG-Ab and MBP-Ab in patients did not predict conversion from a clinically isolated syndrome to MS.
The cellular or molecular basis of the relationship between NMO-Ab and MOG-Ab remains unknown. Both MOG and AQP4 antibodies have been detected in cerebrospinal fluid and sera of NMO patients. The CNS cells that express MOG and those that express AQP4 differ. MOG- or AQP4-specific T cells enter the CNS and might recognize cognate antigen presented by endogenous APC at multiple locations. Microglial cells as antigen-presenting cells are capable of “cross-presenting” MOG and AQP4 (7). Thus, it is possible that these 2 antigens play an important role in the induction of NMO.
The reason why visual acuity of ON patients who are NMO-Ab(+)/MOG-Ab(+) have poor visual recovery may be due to involvement of both astrocytes and oligodendrocytes. Further study of this hypothesis requires recruitment and follow-up of a large group of patients with ON.
1. Biousse V, Newman NJ. Neuro-Ophthalmology Illustrated. New York, NY: Thieme, 2009:183–189.
2. Papais-Alvarenga RM, Carellos SC, Alvarenga MP, Holander C, Bichara RP, Thuler LC. Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Arch Ophthalmol. 2008;126:12–16.
3. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485–1489.
4. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106–2112.
5. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473–477.
6. Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, Kryzer TJ, Lennon VA. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology. 2007;69:2221–2231.
7. Graber DJ, Levy M, Kerr D, Wade WF. Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation. 2008;5:22.
8. Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, Berger T, Lang W, Reindl M, Vincent A, Kristoferitsch W. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008;131:3072–3080.
9. Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, Weinshenker BG. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008;70:2197–2200.
10. Amiguet P, Gardinier MV, Zanetta JP, Matthieu JM. Purification and partial structural and functional characterization of mouse myelin/oligodendrocyte glycoprotein. J Neurochem. 1992;58:1676–1682.
11. Schluesener HJ, Sobel RA, Linington C, Weiner HL. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol. 1987;139:4016–4021.
12. Linington C, Lassmann H. Antibody responses in chronic relapsing experimental allergic encephalomyelitis: correlation of serum demyelinating activity with antibody titre to the myelin/oligodendrocyte glycoprotein (MOG). J Neuroimmunol. 1987;17:61–69.
13. Kerlero de Rosbo N, Milo R, Lees MB, Burger D, Bernard CCA, Ben-Nun A. Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J Clin Invest. 1993;92:2602–2608.
14. von Budingen HC, Hauser SL, Ouallet JC, Tanuma N, Menge T, Genain CP. Frontline: epitope recognition on the myelin/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination. Eur J Immunol. 2004;34:2072–2083.
15. Tanaka K, Tani T, Tanaka M, Saida T, Idezuka J, Yamazaki M, Tsujita M, Nakada T, Sakimura K, Nishizawa M. Anti-aquaporin 4 antibody in Japanese multiple sclerosis with long spinal cord lesions. Mult Scler. 2007;13:850–855.
16. von Büdingen HC, Tanuma N, Villoslada P, Ouallet JC, Hauser SL, Genain CP. Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination. J Clin Immunol. 2001;21:155–170.
17. Marta CB, Oliver AR, Sweet RA, Pfeiffer SE, Ruddle NH. Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology. Proc Natl Acad Sci U S A. 2005;102:13992–13997.
18. Liñares D, Echevarria I, Mañá P. Single-step purification and refolding of recombinant mouse and human myelin oligodendrocyte glycoprotein and induction of EAE in mice. Protein Expr Purif. 2004;34:249–256.
19. O'Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C, Robinson WH, Cherry SV, Bar-Or A, Banwell B, Fukaura H, Fukazawa T, Tenembaum S, Wong SJ, Tavakoli NP, Idrissova Z, Viglietta V, Rostasy K, Pohl D, Dale RC, Freedman M, Steinman L, Buckle GJ, Kuchroo VK, Hafler DA, Wucherpfennig KW. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med. 2007;13:211–217.
20. Guy J, Rao NA. Acute and chronic experimental optic neuritis. Alteration in the blood-optic nerve barrier. Arch Ophthalmol. 1984;102:450–454.
21. Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, Lucchinetti CF, Zéphir H, Moder K, Weinshenker BG. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008;65:78–83.
22. Nagelhus EA, Veruki ML, Torp R, Haug FM, Laake JH, Nielsen S, Agre P, Ottersen OP. Aquaporin-4 water channel protein in the rat retina and optic nerve: polarized expression in Muller cells and fibrous astrocytes. J Neurosci. 1998;18:2506–2519.
23. Merle H, Olindo S, Bonnan M, Donnio A, Richer R, Smadja D, Cabre P. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology. 2007;114:810–815.
24. Lim ET, Berger T, Reindl M, Dalton CM, Fernando K, Keir G, Thompson EJ, Miller DH, Giovannoni G. Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler. 2005;11:492–494.
Supplemental Digital Content
© 2012 Lippincott Williams & Wilkins, Inc.